HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE

HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE

Objective. To perform health economic evaluation of several antirheumatic drugs in patients with rheumatoid arthritis (RA) progressed after DMARDs.Materials and methods. Three consequent line of rheumatoid arthritis therapy in patients progressed after methotrexate were modeled in Russian economic c...

Full description

Bibliographic Details
Main Authors:	A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2016-12-01
Series:	Фармакоэкономика
Subjects:	economic modelling rheumatoid arthritis adalimumab infliximab etanercept tofacitinib
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/154

Similar Items

Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis
by: Bruna O. Ascef, et al.
Published: (2021-07-01)

Redução das imunoglobulinas induzida pelo abatacepte não se associa com eventos infecciosos
by: Valquiria Garcia Dinis
Published: (2017)

Redução das imunoglobulinas induzida pelo abatacepte não se associa com eventos infecciosos
by: Dinis, Valquiria Garcia
Published: (2017)

THE PROBLEMS OF THE SAFETY OF THERAPY WITH TUMOR NECROSIS FACTOR-а INHIBITORS
by: Dmitry Evgenyevich Karateyev
Published: (2009-09-01)

THE PROBLEMS OF THE SAFETY OF THERAPY WITH TUMOR NECROSIS FACTOR-а INHIBITORS
by: Dmitry Evgenyevich Karateyev
Published: (2009-09-01)

Effective use of TNF antagonists
by: Yocum, David
Published: (2004)

Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
by: Tsutomu Takeuchi, et al.
Published: (2021-08-01)

Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
by: Chen HH, et al.
Published: (2016-02-01)

Current views on the pharmacotherapy of psoriatic arthritis
by: G. G. Taradin, et al.
Published: (2016-01-01)

Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
by: Heejin Lim, et al.
Published: (2018-03-01)

Tratamiento biológico en psoriasis: Revisión bibliográfica Biologic therapy of psoriasis: Literature review
by: MS Lorenzetti, et al.
Published: (2012-06-01)

Incidencia de tuberculosis en pacientes con psoriasis que reciben terapias anti- TNF- alfa en Latinoamérica: revisión sistemática y metaanálisis
by: Roniel Gonzalo Contreras Maza
Published: (2019-03-01)

Comparison of several alternative uses of targeted antirheumatic drugs in monotherapy for early rheumatoid arthritis
by: O. V. Shatalova, et al.
Published: (2017-04-01)

Analysis and evaluation of the cost of the treatment anti-TNFα in rheumatoid arthritis and ankylosing spondylitis. Individualised front marketed dose
by: Félix Gómez-De Rueda, et al.
Published: (2017-06-01)

A Review on the Effect of Tumor Necrosis Factor Inhibitors on Structural Progression in Early Axial Spondyloarthritis Using Magnetic Resonance Imaging
by: Ko-Jen Li, et al.
Published: (2019-02-01)

New Treatment Alternatives in the Management of Non-‹nfectious ‹ntraocular ‹nflammations: Biologic Agents
by: Sinan Emre, et al.
Published: (2011-08-01)

Evaluation of Therapeutic Drug Monitoring in the Clinical Management of Patients with Rheumatic Diseases: Data from a Retrospective Single-Center Cohort Study
by: Pedersen L, et al.
Published: (2020-10-01)

The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry
by: Favalli EG, et al.
Published: (2018-05-01)

Targeting psoriasis with new therapies
by: A.Prohić;H. Helppikangas;J. Muhović
Published: (2007-08-01)

Pharmacoeconomic analysis of biological treatments for psoriatic arthritis
by: Mario Eandi, et al.
Published: (2006-09-01)

The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2017-03-01)

UTILIZAÇÃO OFF-LABEL DE TERAPÊUTICA BIOLÓGICA EM DERMATOLOGIA – EXPERIÊNCIA CLÍNICA DE 5 ANOS
by: Filipa Diamantino, et al.
Published: (2016-11-01)

MANAGEMENT OF A PATIENT WITH SEVERE COURSE OF PSORIATIC ARTHRITIS
by: E. I. Alexeeva, et al.
Published: (2013-05-01)

Complicações Imediatas de 3.555 aplicações de agentes anti-TNFα Immediate complications of 3,555 injections of anti-TNFα
by: Júlio César Bertacini de Moraes, et al.
Published: (2010-04-01)

Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study
by: Akhlaghi S, et al.
Published: (2018-10-01)

The marked and rapid therapeutic effect of tofacitinib in combination with subcutaneous methotrexate in a rheumatoid arthritis patient with poor prognostic factors who is resistant to standard disease-modifying antirheumatic drugs and biologicals: A clinical case
by: N. V. Demidova, et al.
Published: (2016-03-01)

How should a patient with rheumatoid arthritis behave after achievement of remission?
by: D. E. Karateev
Published: (2016-03-01)

Systemic Psoriasis Treatment at an Early Age (Part II): Issues of Biological Therapy
by: L. S. Namazova-Baranova, et al.
Published: (2018-02-01)

Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis
by: Paola Di Benedetto, et al.
Published: (2021-08-01)

Comparative evaluation of the effects of synthetic disease-modifying antirheumatic drugs and biological agents on clinical course, the rate of development of destructive changes, and quality of life in patients with rheumatoid arthritis
by: V. I. Mazurov, et al.
Published: (2019-09-01)

Chronic pain and central sensitization in immuno-inflammatory rheumatic diseases: pathogenesis, clinical manifestations, the possibility of using targeted disease modifying antirheumatic drugs
by: A. E. Karateev, et al.
Published: (2019-05-01)

Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts
by: Ruediger B. Mueller, et al.
Published: (2019-09-01)

Complicações Imediatas de 3.555 aplicações de agentes anti-TNFα
by: Júlio César Bertacini de Moraes, et al.

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01)

Sexual dysfunction in a patient with rheumatoid arthritis treated with adalimumab
by: Levent Yazmalar, et al.
Published: (2015-06-01)

Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
by: Ko-Jen Li, et al.
Published: (2021-07-01)

Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry
by: Philip J. Mease, et al.
Published: (2021-09-01)

ROLE OF TUMOR NECROSIS FACTOR ALPHA IN IMMUNE PATHOGENESIS OF DIFFERENT DISEASES AND ITS SIGNIFICANCE FOR EVOLVING ANTICYTOKINE THERAPY WITH MONOCLONAL ANTIBODIES
by: E. V. Voronina, et al.
Published: (2018-12-01)

Health-economic analysis of tocilizumab in patients with rheumatoid arthritis and systemic juvenile arthritis
by: A. S. Kolbin, et al.
Published: (2020-05-01)

Development of Anti-bodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis.
by: Mohammed A. Al-Karkhi, et al.
Published: (2015-10-01)